January 24, 2014 — Cour Pharmaceutical Development Co. Inc. published data in Science Translational Medicine showing the potential of immune modifying nanoparticles (IMP) to reduce inflammation and promote tissue repair and regeneration in patients who have suffered a heart attack.
Animal models injected with IMPs after a heart attack experienced heart lesions reduced by 50 percent, which allowed the heart to pump significantly more blood. IMP treatment showed reduced inflammation and promoted regeneration in all models tested.
The particles are compositions based on polylactic-co-glycolic acid, a biocompatible and biodegradable substance already approved by the U.S. Food and Drug Administration (FDA) for use in a range of therapeutics.
The therapy also showed efficacy in numerous other inflammatory models, specifically in West Nile Virus, encephalitis, peritonitis, multiple sclerosis and inflammatory bowel disease.
For more information: www.courpharma.com
May 02, 2024 
